Biogen Inc. (NASDAQ: BIIB) recently completed spinning off its fast-growing hemophilia drugs into a new company, Bioverativ (NASDAQ: BIVV). The spinoff creates one of the most interesting players in a $10 billion market for hemophilia drugs, but the market is very competitive, and that could create some headwinds. Is Bioverativ a stock worth buying in your portfolio?